SCHEMBL4949798

SCHEMBL4949798

Cc1cc(OCc2nn(-c3ccc(-c4ccccc4)cc3)nc2C)ccc1OCC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 19/20 0.61
PPARG P37231 2/20 0.61
PPARA Q07869 2/20 0.60
FFAR1 O14842 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4954552 0.86 PPARD (0.51) PPARDPPARGPPARA
SCHEMBL4950019 0.86 PPARD (0.61) PPARDPPARA
SCHEMBL4952520 0.83 PPARD (0.51) PPARDPPARGPPARA
SCHEMBL4956335 0.78 PPARD (0.58) PPARDPPARGPPARA
SCHEMBL4952017 0.75 PPARD (0.49) PPARDPPARGPPARA
SCHEMBL4952089 0.75 PPARD (0.56) PPARDPPARGPPARA
SCHEMBL4953545 0.74 PPARD (0.59) PPARDPPARGPPARA
SCHEMBL13292279 0.74 PPARD (0.93) PPARDPPARGPPARAFFAR1
SCHEMBL13292415 0.74 PPARD (0.93) PPARDPPARGPPARAFFAR1
SCHEMBL5959623 0.73 PPARD (0.69) PPARDPPARGPPARAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108630-A1 SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX INC. (US) 2008-05-08 US claimed
US-7323480-B2 Substituted triazoles as modulators of PPAR and methods of their preparation METABOLEX, INC. (US) 2008-01-29 US claimed
US-20060014809-A1 Substituted triazoles as modulators of PPAR and methods of their preparation METABOLEX, INC. (US) 2006-01-19 US claimed
US-20080108630-A1 SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX INC. (US) 2008-05-08 US disclosed
US-20080108630-A1 SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX INC. (US) 2008-05-08 US disclosed
US-20080108630-A1 SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX INC. (US) 2008-05-08 US disclosed
US-7323480-B2 Substituted triazoles as modulators of PPAR and methods of their preparation METABOLEX, INC. (US) 2008-01-29 US disclosed
US-7323480-B2 Substituted triazoles as modulators of PPAR and methods of their preparation METABOLEX, INC. (US) 2008-01-29 US disclosed
US-7323480-B2 Substituted triazoles as modulators of PPAR and methods of their preparation METABOLEX, INC. (US) 2008-01-29 US disclosed
EP-1751120-A2 SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX, INC. (US) 2007-02-14 EP disclosed
US-20060014809-A1 Substituted triazoles as modulators of PPAR and methods of their preparation METABOLEX, INC. (US) 2006-01-19 US disclosed
WO-2005115383-A2 SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION METABOLEX, INC. (US) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014809-A1 Substituted triazoles as modulators of PPAR and methods of their preparation PPARG, PPARD, GPR119 PPARD 2/4885PPARG 1/4885PPARA 4/4885
US-20080108630-A1 SUBSTITUTED TRIAZOLES AS MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION PPARG, PPARD, GPR119 PPARD 2/4885PPARG 1/4885PPARA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.